MORGAN STANLEY PLC/CALL/ABBVIE/165/0.1/20.09.24 Share Price

Warrant

DE000MB09X72

Market Closed - Börse Stuttgart 05:44:38 27/06/2024 pm IST
1.03 EUR -5.50% Intraday chart for MORGAN STANLEY PLC/CALL/ABBVIE/165/0.1/20.09.24
Current month+134.09%
1 month+171.05%
Date Price Change
27/24/27 1.03 -5.50%
26/24/26 1.09 +4.81%
25/24/25 1.04 -10.34%
24/24/24 1.16 +17.17%
21/24/21 0.99 -16.10%

Delayed Quote Börse Stuttgart

Last update June 27, 2024 at 05:44 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ABBVIE INC.
Issuer Morgan Stanley
WKN MB09X7
ISINDE000MB09X72
Date issued 08/11/2022
Strike 165 $
Maturity 20/09/2024 (85 Days)
Parity 10 : 1
Emission price 1.76
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 2.39
Lowest since issue 0.23
Delta0.62x
Omega 10.97
Premium3.24x
Gearing17.84x
Moneyness 1.024
Difference Strike -3.99 $
Difference Strike %-2.42%
Spread 0.01
Spread %1.12%
Theoretical value 0.8850
Implied Volatility 22.05 %
Total Loss Probability 42.02 %
Intrinsic value 0.3727
Present value 0.5123
Break even 174.47 €
Theta-0.03x
Vega0.03x
Rho0.02x

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
-
More about the company

Ratings for AbbVie Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: AbbVie Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
169 USD
Average target price
183.2 USD
Spread / Average Target
+8.43%
Consensus